Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women

Thrombosis Research

Volumn 114, Issue 3, 2004, Pages 155-159

  Alacacioǧlu, Inci ^a   Özcan, Mehmet Ali ^a   Alacacioǧlu, Ahmet ^a   Polat, Mesut ^a   Yüksel, Faize ^a   Demirkan, Fatih ^a   Pişkin, Özden ^a   Özgenç, Yiǧit ^a   Özsan, Hayri Güner ^a   Undar, Bulent ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Coagulation; Fibrinolysis; Preeclampsia; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

D DIMER; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DEVICE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; METABOLISM; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADULT; BIOLOGICAL MARKERS; CARBOXYPEPTIDASE U; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RISK ASSESSMENT; RISK FACTORS;

EID: 4444231438     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.05.012     Document Type: Article

References (21)

1. Dizon-Townson D., Branch D.W. Anticoagulant treatment during pregnancy: an update. Semin. Thromb. Hemost. 24(Suppl. 1):1998;55-62
2. Roberts J.M., Redman C.W. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 341:1993;1447
3. Heilmann L., von Tempelhoff F.G., Gerhold S., Rath W. Effect of thrombophilic factors on thromboembolism and other pregnancy complications. Z. Geburtshilfe Neonatol. 205(4):2001;128-136
4. Maharaj R. Do acetysalicylic and other antiplatelet drugs prevent preeclampsia? Can. Fam. Physician. 47:2001;2480-2482
5. Alfirevic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 101(1):2002;6-14
6. Ricci G., Cerneca F., Simeone R., Alberico S., et al. Coagulation and fibrinolytic parameters in normal and hypertensive pregnancies. J. Matern.-Fetal Investig. 7:1997;129-132
7. Gammaro L., Lippi G., Bottini E., Valenti G., et al. Severe preeclampsia in antithrombin III deficiency with no history of venous thromboembolism. J. Nephrol. 14(4):2001;312-315
8. Schjetlein R., Haugen G., Wisloff F. Markers of intravasculer coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Circulation. 96(2):1997;569-574
9. Schjetlein R., Abdelnoor M., Haugen G., Husby H., et al. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet. Gynecol. Scand. 78(3):1999;191-197
10. Mosnier L.O., von dem Borne P., Meijers J.C., Bouma B.N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb. Haemost. 80:1998;829-835
11. Hori Y, Gabazza E, Yano Y, Katsuki A, Insulin resistance is associated with increased circulating level of thrombin activatable fibrinolysis inhibitor in type 2 diabetic patients. J. Clin. Endocrinol. Metab.
12. Van Tilburg N.H., Rosendaal F.R., Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 95(9):2000;2855-2859
13. Silveira A., Schatteman K., Goossens F., Moor E., Scharpe S., et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb. Haemost. 84:2000;364-368
14. Chetaille P., Alessi M.C., Kouassi D., Morange I., Juhan-vague I. Plasma TAFI antigen variations in healthy subjects. Thromb. Haemost. 83:2000;902-905
15. Chabloz P., Reber G., Boehlen F., Hohfild P., et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br. J. Haematol. 115:2001;150-152
16. Davey D.A., MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 158:1998;892-898
17. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., McLaughlin M.K. Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 161:1989;1200-1204
18. Wang W., Boffa M.B., Bajzar L., Walker J.B. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 273:1998;27176-27181
19. Sakharov D.V., Plow E.F., Rijken D.C. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J. Biol. Chem. 272:1997;14477-14482
20. Hryszko T., Malyszko J., Malyszko J.S., Brzosko S., et al. Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor. Thromb. Res. 104:2001;233-238
21. Antovic J.P., Hamad R.R., Antovic A., et al. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Thromb. Haemost. 88:2002;644-647